Content area

Abstract

INTRODUCTION:

We explored the clinical characteristics, treatment, and outcomes of colitis-associated colorectal cancer (CAC) and compared with sporadic colorectal cancer in Taiwan.

METHODS:

In this retrospective study spanning 1987–2022, CACs diagnosed according to endoscopic and pathological reports from 14 tertiary centers were reported to our cohort. Clinical demographics, endoscopic findings, histological results, treatment modalities, and outcomes were analyzed. Sporadic colorectal cancer data were retrieved from the Cancer Registry Annual Report, Ministry of Health and Welfare, Taiwan.

RESULTS:

We enrolled 65 patients with CAC (median age: 56 years; male: 66.2%). Distal colon was the most common tumor location (41.5%). Of patients with ulcerative colitis, 77.2% had extensive colitis, and 76.5% had Mayo endoscopic subscores of ≥2. Moreover, 50% of lesions were nonpolypoid with indistinct borders in 66.7%. Signet-ring cell subtype consisted of 12.3%. Surveillance colonoscopy adherence was 78.4%, yet 51.3% interval cancers occurred. Disease stage 0–4 distribution was 15%, 20%, 13.3%, 20%, and 31.7%, respectively. Endoscopic resection was feasible for 14%, whereas 67.7% required surgery. During follow-up (median: 21.5 months), we recorded 23.2% recurrence and 34.5% mortality. Lesions with indistinct borders were associated with adverse outcomes (adjusted odds ratio = 11.5 [1.35–98.16]). Colitis-associated rectal cancers, diagnosed later (P < 0.001), had worse outcomes than sporadic rectal cancers.

DISCUSSION:

This is the largest Asian CAC cohort study, emphasizing the need for stringent disease control, improving detection, and reducing interval cancers. Signet-ring cell subtype was prevalent. Rectal colitis-associated cancers were diagnosed later with poorer outcomes than sporadic rectal cancers.

abstract-type="graphical">

Details

1009240
Title
Clinical Characteristics, Management, and Outcomes of Colitis-Associated Colorectal Cancer and the Comparison With Sporadic Colorectal Cancer in Taiwan
Author
Wu, Hsin-Yun 1   VIAFID ORCID Logo  ; Meng-Tzu, Weng 2 ; Jen-Wei, Chou 3 ; Hsu-Heng, Yen 4 ; Chun-Chi, Lin 5 ; Feng-Fan, Chiang 6 ; Chen-Shuan, Chung 7 ; Wei-Chen, Lin 8 ; Chen-Wang, Chang 8 ; Le Puo-Hsien 9 ; Chia-Jung, Kuo 9 ; Ching-Pin, Lin 10 ; Wen-Hung, Hsu 11 ; Chiao-Hsiung, Chuang 12 ; Tsai Tzung-Jiun 13 ; I-Che, Feng 14 ; Shu-Chen, Wei 15   VIAFID ORCID Logo  ; Tien-Yu, Huang 16 

 Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Jinshan Branch, New Taipei City, Taiwan;; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 
 Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan;; Department of Medical Research, National Taiwan University Hospital Hsin-Chu Branch, HsinChu, Taiwan; 
 Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; 
 Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 
 Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; 
 Division of Colorectal Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan; 
 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; 
 Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan; 
 Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan; 
10  Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; 
11  Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan; 
12  Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University College of Medicine, Tainan, Taiwan; 
13  Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 
14  Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan; 
15  Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 
16  Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 
Volume
16
Issue
2
Pages
e00798
Publication year
2025
Publication date
Feb 2025
Section
Article
Publisher
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Place of publication
New York
Country of publication
United States
e-ISSN
2155384X
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Milestone dates
2024-03-06 (Received); 2024-11-26 (Accepted)
ProQuest document ID
3170019546
Document URL
https://www.proquest.com/scholarly-journals/clinical-characteristics-management-outcomes/docview/3170019546/se-2?accountid=208611
Copyright
© 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2025-02-24
Database
ProQuest One Academic